Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 4, 2010, Pages 821-828

  Salvatori, Massimo ^a   Luster, Markus ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; IODINE 123; IODINE 124; IODINE 131; LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

BENIGN TUMOR; CLINICAL TRIAL; DISTANT METASTASIS; DOSE RESPONSE; DOSIMETRY; DRUG DOSE COMPARISON; EUTHYROIDISM; EXTERNAL BEAM RADIOTHERAPY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE 131 UPTAKE TEST; LOW DRUG DOSE; NODULAR GOITER; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PREVALENCE; RADIATION DOSE; REVIEW; THYROID CARCINOMA; THYROID DISEASE; THYROID FUNCTION TEST; THYROID WEIGHT; TOXIC GOITER; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECOMBINANT PROTEINS; THYROID DISEASES; THYROID NEOPLASMS; THYROTROPIN;

EID: 77952093369     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1398-0     Document Type: Review

References (24)

1. JC Sisson AM Avram D Rubello MD Gross 2007 Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging 34 7 1129 1130 10.1007/s00259-007-0419-0 17457585 (Pubitemid 46919562)
2. B Brans L Bodei F Giammarile O Linden M Luster WJG Oyen, et al. 2007 Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" Eur J Nucl Med Mol Imaging 34 5 772 786 10.1007/s00259-006-0338-5 1:STN:280:DC%2BD2s3kvFSktg%3D%3D 17268773 (Pubitemid 46669368)
3. G Flux M Bardies C Chiesa M Monsieurs S Savolainen SE Strand 2007 Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" [letter to the editor] Eur J Nucl Med Mol Imaging 34 10 1699 1700 10.1007/s00259-007-0471-9 17565497 (Pubitemid 47476925)
4. B Shapiro 1993 Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? J Nucl Med 34 10 1638 1641 1:STN:280:DyaK2c%2FhsFCisw%3D%3D 8410274 (Pubitemid 23295370)
5. A de Rooij JP Vandenbroucke JW Smit MP Stokkel OM Dekkers 2009 Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis Eur J Endocrinol 161 5 771 777 10.1530/EJE-09-0286 19671708
6. SR Zakavi Z Mousavi B Davachi 2009 Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule Nucl Med Commun 30 2 169 175 10.1097/MNM.0b013e3283169148 1:CAS:528:DC%2BD1MXhsVyqtrY%3D 19194214
7. MA Walter C Schindler M Christ-Crain J Müller-Brand B Müller 2009 Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models Eur J Clin Invest 39 1 51 57 10.1111/j.1365-2362.2008.02061.x 1:CAS:528: DC%2BD1MXhslOktro%3D 19087129
8. A Traino B Xhafa 2009 Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease Med Phys 36 4 1212 1218 10.1118/1.3093237 1:CAS:528:DC%2BD1MXktVelsrw%3D 19472628
9. C Kobe W Eschner M Wild I Rahlff F Sudbrock M Schmidt, et al. 2010 Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun 31 201 205 10.1097/MNM.0b013e328333d303 1:CAS:528:DC%2BC3cXhtlyrsL0%3D 19907353
10. J Bachmann C Kobe S Bor I Rahlff M Dietlein H Schicha, et al. 2009 Radioiodine therapy for thyroid volume reduction of large goitres Nucl Med Commun 30 6 466 471 10.1097/MNM.0b013e32832b5ccc 19381116
11. S Fast VE Nielsen SJ Bonnema L Hegedüs 2009 Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy Eur J Endocrinol 160 4 517 528 10.1530/EJE-08-0779 1:CAS:528:DC%2BD1MXpsFOktLo%3D 19106244
12. L Braverman RT Kloos B Law Jr M Kipnes M Dionne J Magner 2008 Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters Endocr Pract 14 7 832 839 18996810
13. ER Cubas GJ Paz-Filho M Olandoski CA Goedert LC Woellner GA Carvalho, et al. 2009 Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre Int J Clin Pract 63 4 583 590 10.1111/j.1742-1241.2008.01904.x 1:CAS:528:DC%2BC3cXksVeqs7w%3D 18803554
14. JC Sisson YK Dewaraja EJ Wizauer TJ Giordano AM Avram 2009 Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine Thyroid 19 3 297 303 10.1089/thy.2008.0426 1:CAS:528: DC%2BD1MXivVGktbg%3D 19207003
15. JM De Klerk WJ Oyen 2009 The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases Minerva Endocrinol 34 1 57 69 19209128
16. M Lassmann H Hänscheid C Chiesa C Hindorf G Flux M Luster EANM Dosimetry Committee 2008 EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy Eur J Nucl Med Mol Imaging 35 7 1405 1412 10.1007/s00259-008-0761-x 18491092
17. Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging; 2009 Dec 24. [Epub ahead of print] doi: 10.1007/s00259-009-1303-x.
18. AR Stahl L Freudenberg A Bockisch W Jentzen 2009 A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma Eur J Nucl Med Mol Imaging 36 7 1147 1155 10.1007/s00259-009- 1077-1 1:CAS:528:DC%2BD1MXmvV2rur0%3D 19247651
19. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:270-5. 2009 Sep 4. [Epub ahead of print] doi: 10.1007/s00259-009-1261-3.
20. H Hänscheid M Lassmann M Luster RT Kloos C Reiners 2009 Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma Endocr Relat Cancer 16 4 1283 1289 10.1677/ERC-09-0076 19628649
21. F Capoccetti B Criscuoli G Rossi F Ferretti C Manni E Brianzoni 2009 The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer Q J Nucl Med Mol Imaging 53 5 536 545 1:STN:280:DC%2BD1MjlvFyntg%3D%3D 19910907
22. Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes; 2009. [Epub ahead of print] doi: 10.1055/s-0029-1225350.
23. W Jentzen L Freudenberg EG Eising W Sonnenschein J Knust A Bockisch 2008 Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer J Nucl Med 49 6 1017 1023 10.2967/jnumed.107.047159 18483099 (Pubitemid 351793444)
24. RF Hobbs RL Wahl MA Lodge MS Javadi SY Cho DT Chien, et al. 2009 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison J Nucl Med 50 11 1844 1847 10.2967/jnumed.109.066738 19837771